Back to search
Phase (Ph) I/II study of investigational Aurora A kinase (AAK) inhibitor MLN8237 (alisertib): Updated ph II results in patients (pts) with small cell lung cancer (SCLC), non-SCLC (NSCLC), breast cancer (BrC), head and neck squamous cell carcinoma (HNSCC), and gastroesophageal cancer (GE).
Data up to Jan 2025
Published2013
Citations24
References0
Total Citations Per Year
Abstract
References (0)
No references found
Cited By (0)
No citing papers found in database